Skip to main content

Detail

Christoph Grimm
Associate Prof. PD Christoph Grimm, MD

Department of Obstetrics and Gynecology (Division of General Gynecology and Gynecologic Oncology)
Position: Associate Professor

T +43 1 40400 29620
christoph.grimm@muv.ac.at

Keywords

Cervical Intraepithelial Neoplasia; Hereditary Breast and Ovarian Cancer Syndrome; Nomograms; Ovarian Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms

Research interests

Research interests:

My main research focus is to understand tumor biology of ovarian cancer. Moreover I focus on patient's impaired metabolic function (body composition, serologic markers, and tumor microenvironment) and its implication for treatment and prognosis.

My second research focus is on the development of nomograms to predict treatment response ans prognosis of patients with gynecologic malignancies, i.e. in particulaf in ovarian cancer, endometrial cancer, and cervical cancer.

My third research focus is on the development of a medical treatment for cervical cancer precursor lesions to prevent women from unnecessary surgical therapy - particularly in young women to prevent susequent increase for preterm birth.

Techniques, methods & infrastructure

We work very closely together with the Molecular Oncology Group of the Medical University of Vienna, which is a funding member of the TOC-network (Tumor Bank Ovarian Cancer Network). This has led to two projects funded by the EU within an EU health call in framework program six and seven.

Moreover we have a very intense collaboration with Kliniken-Essen-Mitte, Germany (one of the largest ovarian cancer centers worldwide), Memorial Sloan Kettering Cancer Center, USA, and Charite Berlin, Germany.

Selected publications

  1. Auer, K. et al., 2016. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget. Available at: http://dx.doi.org/10.18632/oncotarget.11038.
  2. Ataseven, B. et al., 2016. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology, 140(2), pp.215-220. Available at: http://dx.doi.org/10.1016/j.ygyno.2015.12.007.
  3. Grimm, C. et al., 2013. Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer. British Journal of Cancer, 109(3), pp.610-614. Available at: http://dx.doi.org/10.1038/bjc.2013.323.
  4. Grimm, C. et al., 2012. Treatment of Cervical Intraepithelial Neoplasia With Topical Imiquimod. Obstetrics & Gynecology, 120(1), pp.152-159. Available at: http://dx.doi.org/10.1097/AOG.0b013e31825bc6e8.
  5. Hefler, L.A. et al., 2008. Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer. Clinical Cancer Research, 14(3), pp.710-714. Available at: http://dx.doi.org/10.1158/1078-0432.CCR-07-1044.